Meningioma Treatment
Meningioma Treatment
There are three main options, and the choice between them depends on the grade, the site, the symptoms and whether the tumour is growing. A small tumour causing nothing is usually observed with scans at intervals. A tumour that is causing symptoms, is growing, or lies where it can be removed safely is treated with surgery, aiming at the whole of the tumour and the strip of covering it arose from. A tumour that cannot be removed safely, or the part left behind after an operation, is treated with precisely aimed radiation.
How the decision is made
Four findings decide which of the options applies, and they are weighed together rather than one at a time:
- Is the tumour causing anything? A tumour that is producing seizures, a visual deficit or a focal weakness needs treatment, because symptoms indicate that the structure next to it is already affected.
- Where does it sit? A tumour over the outer surface of the brain can usually be removed, while one lying against the optic nerve, the nerves for hearing and balance, or a large vein may be better treated with radiation — or with an operation limited to what is safe.
- What is its grade? A grade 1 tumour that is completely removed has a low chance of returning; an atypical or anaplastic tumour is followed more closely and treated with radiation even when removal appeared complete.
- Is it growing? For a tumour causing nothing, the growth measured between two scans is what decides whether to intervene, which is why observation always comes with a schedule rather than with an open-ended wait.
Two principles follow. The first is that doing nothing for now is a treatment decision rather than a failure to decide — it is chosen when the tumour is behaving quietly, and it is reviewed at defined intervals. The second is that the plan is revisited as the tumour and the patient change, because a meningioma is often managed over years and what is appropriate at one point is not necessarily appropriate later.
Observation with scans at intervals
A meningioma is one of the few tumours where waiting and watching is an established option, and understanding why makes it easier to accept or to question:
- Which tumours are observed — small tumours that cause no symptoms, that are not pressing on the nerves of sight or the flow of fluid, and that have not grown on successive scans. This commonly includes tumours found incidentally.
- What the schedule looks like — imaging at defined intervals, more frequent at first and widening if the tumour proves quiet, with the dates given in writing and the comparison made against the previous study.
- What would end the observation — the appearance of symptoms, growth on the scan, or a change that brings the tumour into contact with a structure that cannot be allowed to be affected.
- Why it is reasonable rather than a delay — because many of these tumours grow so slowly that they never cause a problem, and because the risks of operating on a tumour in a difficult position are real and are not worth taking for one that is doing nothing.
- What still has to be done while observing — keeping the schedule, reporting new symptoms between scans, and making sure one centre holds the images, since a comparison cannot be made from a report alone.
Surgery: removing the tumour
Surgery is the treatment that offers the best chance of lasting control, and how far it can go is decided by the structures the tumour lies against:
- What the operation aims at — the tumour together with the strip of covering from which it arose, since leaving that behind is what makes a recurrence likely.
- Where removal can usually be complete — tumours over the outer surface of the brain and along the midline at the front, provided the large vein running along the midline is preserved.
- Where it is deliberately limited — at the base of the skull, where the nerves for sight, smell, hearing and balance, and the arteries supplying the brain, lie immediately against the tumour.
- Embolisation before surgery — for tumours with a rich blood supply, the vessels feeding the tumour are reduced beforehand, which lowers the amount of bleeding during the operation.
- What is reported afterwards — the extent of removal, recorded as a specific finding rather than as complete or incomplete, together with the grade from the tissue removed.
- What the operation may not achieve — a tumour entirely separated from a structure that cannot be sacrificed may leave a residue, which is then treated with precisely aimed radiation rather than re-operated on.
Precisely aimed radiation
Radiation is used either instead of surgery or after it, and the choice between a single treatment and a course of treatment depends on the size and the position of what is being treated:
- Stereotactic radiosurgery — a single, high-precision, high-dose treatment, delivered without opening the skull, used for a small tumour and for the residue left after an operation. It is commonly used at the base of the skull, where an operation carries more risk.
- Fractionated radiotherapy — the same precision divided into a short course of treatments, used for larger tumours and for those lying against structures that cannot tolerate a single high dose, such as the optic nerve.
- After surgery for higher grades — for atypical and anaplastic tumours, radiation is part of the initial plan rather than something held in reserve, because the tumour is more likely to return.
- What it does over time — the tumour usually stops growing and may shrink slowly over months or years, so the measure of success is stability on successive scans rather than an immediate change.
- What it involves — a planning scan, a frame or a mask to hold the head exactly still, and treatment that is not painful; a small area of hair loss and temporary fatigue are the usual effects.
When surgery and radiation are not enough
Drug treatment for meningioma is much less established than for many cancers, and the honest position is that it is considered case by case:
- Where it is considered — a tumour that has returned repeatedly, that is atypical or anaplastic, and for which further surgery and further radiation are no longer appropriate or possible.
- What is used — several drugs have been studied, including agents that act on the blood supply of the tumour and drugs that interfere with the hormonal and signalling pathways the tumour uses; results have been mixed, and no single regimen is standard.
- Why the molecular findings matter here — some of the changes found in meningioma, including those in the AKT1 and SMO pathways, are the subject of research into targeted treatment, so a tumour that has been tested may have options that an untested one does not.
- What to ask — whether drug treatment is being proposed as an established option or within a research setting, what it is expected to achieve, and what the alternatives and the side effects are.
Symptoms, seizures and rehabilitation
Part of the treatment is directed at what the tumour causes rather than at the tumour itself, and it is the part that determines how the patient feels day to day:
- Anti-epileptic medication after a seizure, at the lowest dose that controls it, with attention to interactions with other drugs and with a plan to review it rather than continue it indefinitely.
- Steroids where swelling around the tumour is causing symptoms, used at the lowest effective dose and reduced as soon as it is safe, since prolonged use causes weight gain, raised blood sugar, muscle weakness and mood change.
- Rehabilitation — physiotherapy, speech and language therapy, and cognitive support — which is treatment rather than an optional extra, and which determines how much function is recovered after an operation near critical structures.
- The safety conversation — driving, swimming, working at height and being alone are decided by seizure control and by any deficit present, and should be answered explicitly rather than left to be inferred.
- Vision and hearing support where a deficit persists, including low-vision aids and hearing assessment, since these are practical measures that make a measurable difference.
How the plan is made and reviewed
The decision here sits between the surgeon and the radiation oncologist, and it is best made once rather than in sequence:
- Neurosurgery assesses whether the tumour can be removed, how completely, and with what risk to the structures next to it.
- Radiation oncology assesses whether precisely aimed radiation is the better option, and plans the dose and the volume.
- Neuropathology establishes the grade, which is what determines whether radiation belongs in the plan at all.
- Neuro-ophthalmology, audiology and endocrinology contribute where the tumour threatens vision, hearing or hormonal function.
- Rehabilitation contributes on what function can be recovered and how to pursue it.
- One written plan, with dates, listing what is being done, what each step is for, what would change the plan, and who to contact between reviews — because this is a condition followed over years.